You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in New Zealand

Mar 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Consumer health remains buoyant during 2011

Consumer health remained buoyant during 2011, with value and volume sales increasing within most areas. Interest in self-medication and prevention continued to grow as consumer access to health information and education widened. While still price conscious, New Zealand consumers are becoming increasingly interested in exploring alternative health areas, with demand for herbal and traditional products growing.

Prevention remains a major focus area

Treating the cause of illness rather than symptoms was a key concern of consumers in New Zealand during 2011. Consumers are increasingly interested in preventing consumer health issues from cropping up as opposed to waiting for these issues to manifest themselves as an illness or disease later on. Consequently, demand for vitamins and dietary supplements increased during 2011. Products within this area focus on improving the immune system and strengthening the body.

Vitaco Health continues to lead sales

Vitaco Health ranked first within consumer health in 2011. The company distributes well-established brands such as Healtheries, Nutra-life, Balance and Aussie Bodies. In addition, the company’s success can also be attributed to the fact that it competes within several product areas.

Direct selling channel records growth in 2011

Direct selling remained a significant distribution channel for consumer health during 2011. Sales in this channel increased during the year and direct selling remained the most important non-store retailing channel over the same period. The success of the channel can be attributed to the fact that almost 40% of vitamins and dietary supplements sales are made via direct sellers.

Value sales expected to increase over forecast period

Consumer health constant retail value sales are expected to increase over the forecast period, with demand being fuelled by trends towards self-medication, prevention and natural healing.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in New Zealand with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in New Zealand, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in New Zealand for free:

The Consumer Health in New Zealand market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in New Zealand?
  • What are the major brands in New Zealand?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in New Zealand - Industry Overview

EXECUTIVE SUMMARY

Consumer health remains buoyant during 2011

Prevention remains a major focus area

Vitaco Health continues to lead sales

Direct selling channel records growth in 2011

Value sales expected to increase over forecast period

KEY TRENDS AND DEVELOPMENTS

New Zealand’s ageing population

New Zealand to be smoke-free by 2025

Natural health products bill

Christchurch earthquake

Natural healing and prevention

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 8 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 9 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 10 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Advertising

Packaging

Labelling

Distribution

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC - Switches 2009-2011

DEFINITIONS

SOURCES

  • Summary 2 Research Sources

Consumer Health in New Zealand - Company Profiles

Douglas Pharmaceuticals Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 4 Douglas Pharmaceuticals: Competitive Position 2011

Go Healthy New Zealand Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 6 Go Healthy New Zealand Ltd: Competitive Position 2011

Mylan New Zealand Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Mylan New Zealand Ltd: Competitive Position 2011

Red Seal Natural Health Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 10 Red Seal Natural Health Ltd: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 11 Red Seal Natural Health Ltd: Competitive Position 2011

Vitaco Health Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 13 Vitaco Health Ltd: Competitive Position 2011

Adult Mouth Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Current retail value growth of 2% in 2011 was slightly lower than the review period average of 3% due to the impact of increasing maturity.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser led sales within adult mouth care in 2011, recording a retail value share of 36%. The company distributes Bonjela Oral Gel, which was the number one ranked adult mouth care brand in 2011.

PROSPECTS

  • Adult mouth care’s projected constant retail value CAGR of 1% is higher than the review period average of 0%. Despite this fact, price competition is expected to intensify over the forecast period. In addition, the lack of significant growth drivers will also result in the area only recording moderate growth.

CATEGORY DATA

  • Table 11 Sales of Adult Mouth Care: Value 2006-2011
  • Table 12 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 13 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 14 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 15 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 16 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Analgesics current retail value growth of 1% in 2011 was lower than the review period average of 2%, partly as a result of decreasing acetaminophen sales. Acetaminophen accounted for 39% of analgesics current retail value sales in 2011. In addition to falling sales within acetaminophen, aspirin has also reached a very high level of maturity.

SWITCHES

  • Summary 14 Switches 2010-2011

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline led sales in 2011 with a retail value share of 41% and sales of NZ$19 million while Reckitt Benckiser ranked second with a retail value share of 33% and sales of NZ$15 million. Both of these companies are highly successful within analgesics due to the fact that their brands enjoy a high level of brand awareness and they invest strongly in marketing and advertising. Consequently, competition between the two companies is intense. During 2011, Reckitt Benckiser recorded a 3% increase in retail value sales whereas GlaxoSmithKline recorded a 1% decline in sales. This led to a narrowing of the gap between these two major firms within analgesics.

PROSPECTS

  • Intense competition will limit value growth within analgesics over the forecast period, with the area having a projected constant retail value CAGR of 0%.

CATEGORY DATA

  • Table 17 Sales of Analgesics by Category: Value 2006-2011
  • Table 18 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 19 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 20 Analgesics Company Shares by Value 2007-2011
  • Table 21 Analgesics Brand Shares by Value 2008-2011
  • Table 22 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 23 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The 5% increase in current retail value sales in 2011 was in-line with the review period CAGR. Furthermore, growth in 2011 was similar to that from 2009 to 2010. This highlights increasing consumer demand for products that help to provide a good night’s sleep. Steady growth also points to the fact that an increasing number of individuals have busy and stressful lives and that sleeping disorder incidence is on the rise.

SWITCHES

COMPETITIVE LANDSCAPE

  • Vitaco Health led calming and sleeping sales in 2011, recording a retail value share of 43%. The company offers a wide range of products such as Be Sleepy Tea, Healtheries Easy Sleep tablets, Healtheries Bedtime Tea and Nutra-life Sleep Well capsules. The fact that the Healtheries range is available in supermarkets as well as chemists and pharmacies makes it more accessible to consumers.

PROSPECTS

  • Growing consumer health and wellness awareness is expected to be a major growth driver within calming and sleeping in New Zealand over the forecast period, with constant retail value sales projected to increase at an average annual rate of 2%.

CATEGORY DATA

  • Table 24 Sales of Calming and Sleeping: Value 2006-2011
  • Table 25 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 26 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 27 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 28 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 29 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in New Zealand - Category Analysis

HEADLINES

TRENDS

  • During 2010, the Associate Minister of Health introduced the Misuse of Drugs Amendment Bill which reclassified pseudoephedrine and ephedrine as Class B2 controlled drugs. This followed an agreement by the cabinet in September 2009 to reclassify these two drugs considering the fact they are active ingredients used in the manufacture of the Class A controlled drug methamphetamine. Prior to the reclassification, pseudoephedrine was available over the counter in cold and flu remedies from pharmacies. However, ephedrine was a prescription only product. Post-reclassification, pseudoephedrine has become a prescription-only product while ephedrine remains a prescription-only product.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser led cough, cold and allergy (hay fever) remedies during 2011 with a retail value share of 28%. The company’s flagship brands include Lemsip, Strepsils and Nurofen. The company’s value sales increased by 2% in 2011 on the strength of its well-established brands. In addition, the company also utilises high levels of advertising to promote these three brands. Lemsip was the top performing brand within cough, cold and allergy (hay fever) in 2011, recording a retail value share of 14%.

PROSPECTS

  • Cough, cold and allergy (hay fever) remedies’ projected forecast period constant retail value CAGR of 1% is above the review period average of 0%. Value sales will be negatively impacted by the reclassification of codeine, pseudoephedrine, phenylephrine and dextromethorphan over the coming years, hence forecast growth is expected to be moderate.

CATEGORY DATA

  • Table 30 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 32 Sales of Decongestants by Category: Value 2006-2011
  • Table 33 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 34 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 36 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 38 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Digestive remedies is a mature area and thus only recorded moderate current retail value growth of 1% in 2011. Towards the latter end of the review period, consumers were extremely price conscious and this trend continued within digestive remedies during 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson led digestive remedies in 2011, recording a retail value share of 24%. The company’s major brands include Mylanta (antacids and antiflatulents), Imodium (diarrhoeal remedies), Microlax (laxative) and Dramamine (motion sickness remedies). Mylanta Double Strength recorded a retail value share of 60% within antiflatulents in 2011 while Mylanta recorded a retail value share of 26% within antacids. Imodium was the top performing diarrhoeal remedy during 2011.

PROSPECTS

  • Digestive remedies’ projected forecast period constant retail value CAGR of 0% is higher than the review period average of -1%. Static forecast growth is due to the impact of increasing maturity within the category. Furthermore, substantial innovation and promotion is not expected within this area over the forecast period.

CATEGORY DATA

  • Table 40 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 41 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 42 Digestive Remedies Company Shares by Value 2007-2011
  • Table 43 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 44 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 45 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Ear care current retail value growth of 1% in 2011 was lower than the review period average of 3%. Growth rates are declining within the area due to stagnation. There were no unique or significant growth drivers to boost value sales during the year.

SWITCHES

COMPETITIVE LANDSCAPE

  • Norgine ranked first within ear care in 2011 with a retail value share of 30%. The company’s success can be attributed to the popularity of its Waxsol brand.

PROSPECTS

  • Ear care’s projected forecast period constant retail value CAGR of 1% is higher than the review period average of 0%. Modest growth predictions result from a decline in the number of new developments capable of boosting growth. Constant retail value sales are projected to reach NZ$2.3 million by 2016.

CATEGORY DATA

  • Table 46 Sales of Ear Care: Value 2006-2011
  • Table 47 Sales of Ear Care: % Value Growth 2006-2011
  • Table 48 Ear Care Company Shares by Value 2007-2011
  • Table 49 Ear Care Brand Shares by Value 2008-2011
  • Table 50 Forecast Sales of Ear Care: Value 2011-2016
  • Table 51 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Emergency contraception current retail value growth of 6% in 2011 was higher than the review period CAGR of 5% due to the fact that the unit price of Levonelle increased from NZ$43.89 per pill in 2010 to NZ$45.91 in 2011. During 2009, the Auckland District Health Board spent NZ$300,000 on a trial and paid pharmacies to make Levonelle available for free for five months ending in March 2009. The free pills were distributed to approximately 8,000 patients (even those aged between 10 and 14). As a result of the trial, the number of abortions declined. However, the decline was so small as to be considered statistically insignificant.

COMPETITIVE LANDSCAPE

  • There is only one OTC emergency contraception product available in New Zealand, Levonelle. The brand is distributed by Schering (NZ), which is a part of Bayer AG. As a result, Levonelle continued to account for 100% of retail value sales during 2011.

PROSPECTS

  • Emergency contraception’s projected forecast period constant retail value CAGR of 3% is higher than the review period CAGR of 2%. This suggests that unit prices are expected to climb over the forecast period. Nonetheless, other factors will also impact emergency contraception sales, including subsidies for prescription emergency contraception, new contraceptive methods and increasing consumer education regarding preventative contraception.

CATEGORY DATA

  • Table 52 Sales of Emergency Contraception: Value 2006-2011
  • Table 53 Sales of Emergency Contraception: % Value Growth 2006-2011
  • Table 54 Emergency Contraception Company Shares by Value 2007-2011
  • Table 55 Emergency Contraception Brand Shares by Value 2008-2011
  • Table 56 Forecast Sales of Emergency Contraception: Value 2011-2016
  • Table 57 Forecast Sales of Emergency Contraception: % Value Growth 2011-2016

Eye Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Current retail value growth of 4% in 2011 was in-line with the review period average. While standard eye care is a mature area, allergy eye care is more dynamic.

SWITCHES

COMPETITIVE LANDSCAPE

  • Allergan New Zealand, Alcon NZ and Prestige Brands International lead eye care sales in New Zealand. Allergan New Zealand led sales in 2011, recording a retail value share of 26%. The company has one major allergy eye care brand, Albalon, which recorded a brand retail value share of 3% during 2011. Within standard eye care, the company’s brands include Refresh, Prefrin and Albalon.

PROSPECTS

  • Eye care’s projected forecast period constant retail value CAGR of 2% is higher than the review period average of 1%. Modest forecast growth is due to increasing maturity within standard eye care. In addition, intense competition within standard eye care will put downwards pressure on unit prices over the forecast period.

CATEGORY DATA

  • Table 58 Sales of Eye Care by Category: Value 2006-2011
  • Table 59 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 60 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 61 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 62 Eye Care Company Shares by Value 2007-2011
  • Table 63 Eye Care Brand Shares by Value 2008-2011
  • Table 64 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 65 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in New Zealand - Category Analysis

HEADLINES

TRENDS

  • In April 2009, two political parties (the National Party and the Green Party) announced their intention to work together to develop a New Zealand-based regulatory system for natural health products sold in New Zealand. In March 2010, the Ministry of Health made available a consultation paper on the development of the proposed Natural Health Products Bill with public submissions closing in May 2010. Key elements of the proposed scheme include: product approval (based on notification of products on a database), recognition of the decisions of trusted overseas regulators, lists of prohibited and permitted ingredients and a process for establishing new ingredients, labelling requirements, advertising rules, export certification and a tailor-made manufacturing code of practice. The Associate Minister of Health, Dr Jonathan Coleman, noted that existing legislation was obsolete and that there was a need for a regulatory system that lent assurance to New Zealand consumers about the efficacy and safety of natural health products. In addition, the aim of the system was to be cost-effective and therefore not impose high costs on industry players.

COMPETITIVE LANDSCAPE

  • Vitaco Health led herbal and traditional product sales in 2011, recording a retail value share of 12%. The company distributes its flagship Healtheries brand, which ranked first within herbal and traditional products in 2011 with a retail value share of 8%.

PROSPECTS

  • Herbal and traditional products has a projected forecast period constant retail value CAGR of 2%, with sales expected to reach NZ$80 million by 2016. This projected growth is higher than review period CAGR of -1% and suggests that herbal and traditional products will continue to increase in popularity over the forecast period.

CATEGORY DATA

  • Table 66 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 67 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 68 Herbal/Traditional Products Company Shares 2007-2011
  • Table 69 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 70 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 71 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • During 2010, Regulatory Reform Minister, Rodney Hide, introduced the Regulatory Responsibility Bill to review and remove hundreds of regulations that are considered to hinder business practice in New Zealand. With regard to medicated skin care, this review was intended to reduce compliance costs for manufacturers and importers of ‘related products’ among other things. Related products are defined in Section 94 of the Medicines Regulations Act 1984 as ‘a product that is primarily a food, dentifrice or cosmetic but which has a secondary therapeutic use’. Examples of such products include anti-dandruff shampoos, fluoride toothpaste and nappy rash treatments. Prior to this bill being introduced ‘related products’ were double-regulated and high compliance costs made it difficult for manufacturers to introduce new products.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson led medicated skin care sales in 2011, recording a retail value share of 24%. The company distributes the popular Regaine (hair loss treatment), Nizoral (medicated shampoo) and Daktarin (topical antifungals) brands. These products enjoy high brand awareness in New Zealand and are well-established. Regaine (formerly Rogaine) was the top brand within hair loss treatments in 2011, accounting for some 96% of retail value sales. Nizoral led sales within medicated shampoos in 2011 with a retail value share of 34%.

PROSPECTS

  • Medicated skin care has a projected forecast period constant retail value CAGR of 1%. Only moderate growth is expected over the forecast period due to strong competition from prescription-only, cosmeceutical and natural skin care products.

CATEGORY DATA

  • Table 72 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 73 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 74 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 75 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 76 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 77 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 78 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in New Zealand - Category Analysis

HEADLINES

TRENDS

  • NRT smoking cessation aids current retail value growth of 8% in 2011 was slightly higher than the review period average of 7%. One of the biggest changes to tobacco excise taxation over the review period occurred during 2010, when the government implemented a range of excise tax increases levied on cigarettes, cigars, cigarillos and loose tobacco. As a result of these changes, there was a surge in the number of consumers opting to quit smoking – a development which boosted NRT smoking cessation aids value sales.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson led NRT smoking cessation aids during 2011, recording a retail value share of 72%. The company distributes the popular Nicorette brand, which includes gum, patches, inhalers and microtabs.

PROSPECTS

  • The New Zealand government has made a commitment to becoming smoke-free by 2025. Consequently, smoking in New Zealand is becoming increasingly taboo, with smokers having fewer and fewer areas where they can smoke. Bans on smoking indoors and the increase in excise taxation on tobacco products have put significant pressure on smokers. As a result, the total number of smokers is expected to drop from 674,300 in 2011 to 586,360 by 2016.

CATEGORY INDICATORS

  • Table 79 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 80 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 81 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 82 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 83 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 84 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 85 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

OTC Triptans in New Zealand - Category Analysis

HEADLINES

TRENDS

  • In June 2006, sumatriptan was reclassified from a prescription medicine to a restricted medicine (sold by a pharmacist in a pharmacy). This reclassification applied to packs of no more than two 50mg tablets. As a result of this reclassification, three different triptan products were commonly available, Sumagran Active, Imigran and Arrow Sumatriptan. In May 2010, Pharmac announced that it would stop subsidising Imigran and Sumagran Active and begin subsidising Arrow-Sumatriptan by Arrow Pharmaceuticals (tablets and injections) solely. This arrangement is expected to continue until June 2013. Imigran and Arrow-Sumatripan are prescription medicines while Sumagran Active is a restricted medicine (pharmacist only).

SWITCHES

COMPETITIVE LANDSCAPE

  • Mygran, an Arrow Pharmaceuticals brand, was discontinued in 2009. This left Sumagran Active as the only OTC triptan available during 2010.

PROSPECTS

  • OTC triptans has a projected forecast period constant retail value CAGR of 5%, with growth set to be fuelled by the fact that a growing number of triptans are being switched from prescription products to restricted medicines. It is not expected that many OTC triptans products will become general sale medicines over the forecast period.

CATEGORY DATA

  • Table 87 Sales of OTC Triptans: Value 2007-2011
  • Table 88 Sales of OTC Triptans: % Value Growth 2007-2011
  • Table 89 OTC Triptans Company Shares by Value 2007-2011
  • Table 90 OTC Triptans Brand Shares by Value 2008-2011
  • Table 91 Forecast Sales of OTC Triptans: Value 2011-2016
  • Table 92 Forecast Sales of OTC Triptans: % Value Growth 2011-2016

Sports Nutrition in New Zealand - Category Analysis

HEADLINES

TRENDS

  • During 2009 and 2010, sports nutrition sales were negatively impacted by the economic recession. However, this trend reversed in 2011, with current retail value sales increasing by 4% as a result of the improving economy.

COMPETITIVE LANDSCAPE

  • Vitaco Health led sports nutrition in 2011 with a retail value share of 38%. The company recorded a 12% increase in retail value sales in 2011 and its two flagship brands are Aussie Bodies and Balance. Balance Muscle 2 Go Protein Bars was the leading brand within bars in 2011, recording a retail value share of 46%. The brand also led sales within powder and non-protein products, where it recorded respective retail value shares of 34% and 41%. Balance has a strong presence in gyms, sports nutrition stores, chemists and pharmacies and sports good stores. Furthermore, consumer awareness of the Balance brand is high due to its sponsorship of numerous athletes. Balance products are divided into consumer goal areas such as endurance, joint support and muscle recovery.

PROSPECTS

  • Sports nutrition has a projected forecast period constant retail value CAGR of 0%, with total retail value sales expected to fall slightly to NZ$17 million by 2016.

CATEGORY DATA

  • Table 93 Sales of Sports Nutrition: Value 2006-2011
  • Table 94 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 95 Sports Nutrition Company Shares 2007-2011
  • Table 96 Sports Nutrition Brand Shares 2008-2011
  • Table 97 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 98 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The fact that current retail value growth of 6% in 2011 was higher than the review period average of 5% highlights the impact of increasing interest in the area.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Vitaco Health ranked first within vitamins and dietary supplements in 2011, recording a retail value share of 22%. The fact that the company’s retail value share has increased from 21% in 2007 highlights the strong performance of its two key brands: Healtheries and Nutra-Life. The Healtheries brand is well-established in New Zealand and a trusted source of health and wellbeing products. Healtheries was the number one vitamins and dietary supplements brand during 2011, recording a retail value share of 14%. The brand is available in most vitamins and dietary supplements areas and performed well within individual dietary supplements (echinacea, garlic) and single vitamins.

PROSPECTS

  • Vitamins and dietary supplements has a projected forecast period constant retail value CAGR of 3%, with sales expected to reach NZ$265 million by 2016. This is higher than the review period CAGR of 2%. Forecast growth predictions have been moderated due to the expected negative impact of pending changes and additions to regulations surrounding natural health products in New Zealand. Furthermore, the fact that consumers are expected to remain price sensitive over the forecast period means manufacturers will focus on being price competitive.

CATEGORY DATA

  • Summary 15 Dietary Supplements Brand Ranking by Positioning 2011
  • Table 99 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 100 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 101 Dietary Supplements by Positioning 2006-2011
  • Table 102 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 103 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 104 Vitamins Brand Shares by Value 2008-2011
  • Table 105 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 106 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 107 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in New Zealand - Category Analysis

HEADLINES

TRENDS

  • According to the 2006/2007 New Zealand Health Survey, the age-standardised obesity prevalence rate for the population aged 15 years and over is 25% - an increase from the 24% recorded in 2002/2003 and the 19% recorded in 1997. In 2006/2007, some 8% of children aged between 5 and 14 years of age were obese – a slight decline from the 9% recorded in 2002. However, in general obesity rates are on the rise in New Zealand. Obesity also tends to be more prevalent among Maori, Pacific Island and South Asian communities in New Zealand.

COMPETITIVE LANDSCAPE

  • Vitaco Health was the leading player within weight management in 2011, recording a retail value share of 28%. The company distributes the Nutra-life and Healtheries brands, which each recorded brand retail value shares of 14% in 2011. The two brands ranked first and second respectively within weight management and were present in both meal replacement slimming as well as weight loss supplements.

PROSPECTS

  • Weight management has a projected forecast period constant retail value CAGR of 2%, with sales expected to reach NZ$46 million by 2016. Growth in this area will primarily be fuelled by the efforts of the Ministry of Health to combat obesity. As a result, obesity rates are expected to drop as weight management value sales increase. Consumers are expected to remain interested in health and wellness and greater access to information and education on this topic will further fuel interest in maintaining an active and healthy life.

CATEGORY DATA

  • Table 108 Sales of Weight Management: Value 2006-2011
  • Table 109 Sales of Weight Management: % Value Growth 2006-2011
  • Table 110 Weight Management Company Shares 2007-2011
  • Table 111 Weight Management Brand Shares 2008-2011
  • Table 112 Forecast Sales of Weight Management: Value 2011-2016
  • Table 113 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Current retail value growth of 2% in 2011 was lower than the review period average of 3% due to the impact of increasing maturity. During 2011, there were no new innovations within the area. However, Elastoplast did launch one new product.

COMPETITIVE LANDSCAPE

  • The most popular wound care brand in 2011 was Band-Aid from Johnson & Johnson, which recorded a retail value share of 21%. The brand maintained its sales share over the review period due to high consumer awareness and a well-established brand presence. Johnson & Johnson thus led sales within the area, recording a retail value share of 25%. The company was the leading performer within sticking plasters and adhesive bandages during 2011 and over the review period.

PROSPECTS

  • Wound care has a projected forecast period constant retail value CAGR of 1%, with sales set to reach NZ$11.5 million by 2016.

CATEGORY DATA

  • Table 114 Sales of Wound Care by Category: Value 2006-2011
  • Table 115 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 116 Wound Care Company Shares by Value 2007-2011
  • Table 117 Wound Care Brand Shares by Value 2008-2011
  • Table 118 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 119 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Green Tea Extract
            • Microalgae
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Paediatric Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Paediatric Consumer Health
        • Paediatric Analgesics
          • Paediatric Acetaminophen
          • Paediatric Aspirin
          • Paediatric Combination Products - Analgesics
          • Paediatric Diclofenac
          • Paediatric Dipyrone
          • Paediatric Ibuprofen
          • Paediatric Ketoprofen
          • Paediatric Naproxen
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Paediatric Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Paediatric Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market sizes
    • Company shares
    • Brand shares
    • Distribution
    • Analysis by format
    • Analysis by positioning
    • Analysis by type
    • Herbal/traditional vs standard
    • Pricing
    • Smoking population - number of adult smokers
    • Smoking prevalence - % of adult population

    Market size details:

    • Retail volume
    • Retail volume % growth
    • Retail volume per capita
    • Retail value retail selling price % growth
    • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price % growth
    • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?

    If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!